193 related articles for article (PubMed ID: 29939287)
1. EVI1 carboxy-terminal phosphorylation is ATM-mediated and sustains transcriptional modulation and self-renewal via enhanced CtBP1 association.
Paredes R; Schneider M; Stevens A; White DJ; Williamson AJK; Muter J; Pearson S; Kelly JR; Connors K; Wiseman DH; Chadwick JA; Löffler H; Teng HY; Lovell S; Unwin R; van de Vrugt HJ; Smith H; Kustikova O; Schambach A; Somervaille TCP; Pierce A; Whetton AD; Meyer S
Nucleic Acids Res; 2018 Sep; 46(15):7662-7674. PubMed ID: 29939287
[TBL] [Abstract][Full Text] [Related]
2. EVI1 phosphorylation at S436 regulates interactions with CtBP1 and DNMT3A and promotes self-renewal.
Paredes R; Kelly JR; Geary B; Almarzouq B; Schneider M; Pearson S; Narayanan P; Williamson A; Lovell SC; Wiseman DH; Chadwick JA; Jones NJ; Kustikova O; Schambach A; Garner T; Amaral FMR; Pierce A; Stevens A; Somervaille TCP; Whetton AD; Meyer S
Cell Death Dis; 2020 Oct; 11(10):878. PubMed ID: 33082307
[TBL] [Abstract][Full Text] [Related]
3. EVI1 oncoprotein expression and CtBP1-association oscillate through the cell cycle.
Paredes R; Schneider M; Pearson S; Teng HY; Kelly JR; Pierce A; Somervaille TCP; Whetton AD; Meyer S
Mol Biol Rep; 2020 Oct; 47(10):8293-8300. PubMed ID: 32979164
[TBL] [Abstract][Full Text] [Related]
4. Oncogene
Pastoors D; Havermans M; Mulet-Lazaro R; Brian D; Noort W; Grasel J; Hoogenboezem R; Smeenk L; Demmers JAA; Milsom MD; Enver T; Groen RWJ; Bindels E; Delwel R
Sci Adv; 2024 May; 10(20):eadk9076. PubMed ID: 38748792
[TBL] [Abstract][Full Text] [Related]
5. EVI1 induces autophagy to promote drug resistance via regulation of ATG7 expression in leukemia cells.
Niu Y; Yang X; Chen Y; Jin X; Li L; Guo Y; Li X; Xie Y; Zhang Y; Wang H
Carcinogenesis; 2020 Jul; 41(7):961-971. PubMed ID: 31593983
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of the leukemic oncoprotein EVI1 on serine 196 modulates DNA binding, transcriptional repression and transforming ability.
White DJ; Unwin RD; Bindels E; Pierce A; Teng HY; Muter J; Greystoke B; Somerville TD; Griffiths J; Lovell S; Somervaille TC; Delwel R; Whetton AD; Meyer S
PLoS One; 2013; 8(6):e66510. PubMed ID: 23776681
[TBL] [Abstract][Full Text] [Related]
7. EVI1 dysregulation: impact on biology and therapy of myeloid malignancies.
Birdwell C; Fiskus W; Kadia TM; DiNardo CD; Mill CP; Bhalla KN
Blood Cancer J; 2021 Mar; 11(3):64. PubMed ID: 33753715
[TBL] [Abstract][Full Text] [Related]
8. EVI1 protein interaction dynamics: Targetable for therapeutic intervention?
Paredes R; Doleschall N; Connors K; Geary B; Meyer S
Exp Hematol; 2022 Mar; 107():1-8. PubMed ID: 34958895
[TBL] [Abstract][Full Text] [Related]
9. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
[TBL] [Abstract][Full Text] [Related]
10. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.
Maicas M; Vázquez I; Alis R; Marcotegui N; Urquiza L; Cortés-Lavaud X; Cristóbal I; García-Sánchez MA; Odero MD
Biochim Biophys Acta Gene Regul Mech; 2017 Jun; 1860(6):721-729. PubMed ID: 28391050
[TBL] [Abstract][Full Text] [Related]
11. Prdm3 and Prdm16 cooperatively maintain hematopoiesis and clonogenic potential.
McGlynn KA; Sun R; Vonica A; Rudzinskas S; Zhang Y; Perkins AS
Exp Hematol; 2020 May; 85():20-32.e3. PubMed ID: 32437910
[TBL] [Abstract][Full Text] [Related]
12. Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements.
Sitailo S; Sood R; Barton K; Nucifora G
Leukemia; 1999 Nov; 13(11):1639-45. PubMed ID: 10557037
[TBL] [Abstract][Full Text] [Related]
13. Evi1 forms a bridge between the epigenetic machinery and signaling pathways.
Yoshimi A; Kurokawa M
Oncotarget; 2011 Jul; 2(7):575-86. PubMed ID: 21795762
[TBL] [Abstract][Full Text] [Related]
14. The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.
Ottema S; Mulet-Lazaro R; Erpelinck-Verschueren C; van Herk S; Havermans M; Arricibita Varea A; Vermeulen M; Beverloo HB; Gröschel S; Haferlach T; Haferlach C; J Wouters B; Bindels E; Smeenk L; Delwel R
Nat Commun; 2021 Sep; 12(1):5679. PubMed ID: 34584081
[TBL] [Abstract][Full Text] [Related]
15. Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis.
Kataoka K; Kurokawa M
Cancer Sci; 2012 Aug; 103(8):1371-7. PubMed ID: 22494115
[TBL] [Abstract][Full Text] [Related]
16. The role of EVI1 in myeloid malignancies.
Glass C; Wilson M; Gonzalez R; Zhang Y; Perkins AS
Blood Cells Mol Dis; 2014; 53(1-2):67-76. PubMed ID: 24495476
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.
Vázquez I; Maicas M; Cervera J; Agirre X; Marin-Béjar O; Marcotegui N; Vicente C; Lahortiga I; Gomez-Benito M; Carranza C; Valencia A; Brunet S; Lumbreras E; Prosper F; Gómez-Casares MT; Hernández-Rivas JM; Calasanz MJ; Sanz MA; Sierra J; Odero MD
Haematologica; 2011 Oct; 96(10):1448-56. PubMed ID: 21750091
[TBL] [Abstract][Full Text] [Related]
18. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells.
Senyuk V; Chakraborty S; Mikhail FM; Zhao R; Chi Y; Nucifora G
Oncogene; 2002 May; 21(20):3232-40. PubMed ID: 12082639
[TBL] [Abstract][Full Text] [Related]
19. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
20. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; van Putten WL; Valk PJ; van der Poel-van de Luytgaarde S; Hack R; Slater R; Smit EM; Beverloo HB; Verhoef G; Verdonck LF; Ossenkoppele GJ; Sonneveld P; de Greef GE; Löwenberg B; Delwel R
Blood; 2003 Feb; 101(3):837-45. PubMed ID: 12393383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
